

## The Strategic Reserve

Cytiva is committed to support customers who use our products in their production of Biopharmaceuticals. For that reason we hold an extensive 'Strategic Reserve' of our chromatography resins (the "**Reserve**").

### *What is the Reserve?*

Our Reserve is first and foremost a security-of-supply commitment to Cytiva's customers that use our resins in approved and registered manufacturing processes for human therapeutics and vaccines, and other critical needs as Cytiva may determine including unusual peaks in demand (e.g. from COVID-19). The Reserve is part of our business continuity plan and is intended for use where there is an event outside of Cytiva's control that could have a significant business impact on Cytiva and which could affect Cytiva's ability to respond to demand for chromatography resins manufactured in Uppsala, Sweden (a "**Business Impact Event**"). The Reserve is primarily aimed at providing a reliable supply of resin during a Business Impact Event and the subsequent recovery phase. The Reserve is intended to cover approximately 6 to 12 months' customer demand, depending on resin type and our estimated recovery time. The levels targeted in the Reserve are based on our customers' historical demand for resins and (to the best of our knowledge) their use of such material in approved manufacturing processes for human therapeutics and vaccines. Currently the Reserve is located in two separate facilities, both facilities also being independent from our manufacturing sites. Resin types, volumes and storage locations of the Reserve are regularly reviewed to ensure effective deployment of materials globally should an incident occur. In addition, to maximize the shelf-life of the resin, the content of the Reserve is rotated on a regular basis. The Reserve does not generally include customized resins or resins with a remaining shelf-life of less than two years.

### *How is the Reserve used?*

The Reserve is not allocated for any specific customer and will not be used as safety stock in the event of an incident at a customer's manufacturing site. In addition, the Reserve is not intended for deliveries of regular orders or to compensate for temporary production variations. Where Cytiva determines a need to use the Reserve, a controlled order intake process will be implemented to minimize impact for customers during the resin production recovery period. Withdrawals from the Reserve will be prioritized by Cytiva, on a case by case basis, considering factors including urgency and the immediate use of the resin in any approved manufacturing process for human therapeutics or vaccines.

Uppsala, Sweden, • 2021



Emmanuel Ligner  
President, Cytiva  
Cytiva



Mary Blenn  
VP Global Supply Chain  
Cytiva